Tailwinds' Take: solid guidance for the Q is well ahead of street forecasts.  MEDFORD, N.Y., Feb. 06, 2019 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc.(Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today preliminary estimates of revenue for the fourth...
MEDFORD, N.Y., Jan. 17, 2019 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc.(Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will host an analyst and institutional investor meeting on Wednesday, February 6, 2019, in New York City from 8:30 a.m. to approximately 10:30...
MEDFORD, N.Y., Jan. 07, 2019 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc.(Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced that it has received a CE mark for its diagnostic test developed in collaboration with AstraZeneca, a global biopharmaceutical company. Chembio...
MEDFORD, N.Y., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc.(NASDAQ: CEMI) (“Chembio”), a provider of point-of-care diagnostic tests for infectious diseases, announced today the pricing of its previously announced underwritten registered public offering of 2,370,435 shares of its common stock at...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.